How to Get a GLP-1 Without Insurance

The short answer

You do not need insurance to start a GLP-1. There are three working routes for a cash-paying mother: buying an FDA-approved brand drug direct from the manufacturer's self-pay program, seeing a local prescriber and paying a cash pharmacy price, or going through a telehealth clinic.

The ordering here has changed, and it matters. For years the standard advice sent uninsured patients to telehealth compounded vials because they were far cheaper. In 2026 they are often not cheaper, and the regulatory ground under them has shifted. The manufacturers now sell the approved drugs direct for somewhere between $149 and $449 a month depending on the drug and the dose — so for most families the FDA-approved route is now both the safest and the least expensive. Here is how each one actually works.

First, know what you are eligible for

GLP-1 weight-management medicines are prescribed against clinical criteria, not insurance status — generally a body-mass index in the obesity range, or the overweight range with a weight-related condition. A prescriber makes that call, and a legitimate route always involves one. That is true whether you fill in a telehealth intake form or sit in an office.

The evidence base behind the prescription is real: semaglutide produced about 15% mean weight loss in the STEP 1 trial¹ and tirzepatide near 20% in SURMOUNT-1², which is why clinicians treat these as long-term metabolic medicines rather than a quick fix. If you are brand new to all of this, read starting a GLP-1 as a first-timer alongside this piece.

Route 1 — Buy the approved drug direct from the maker

This is the route that changed. Both manufacturers now run self-pay pharmacies for people without coverage, and they publish the prices.

Novo Nordisk's terms put Wegovy at "$199 for each month of 0.25 mg & 0.5 mg" for two monthly fills, then "$349 per month" for the standard pen doses, with the higher-dose HD pen at $399³. Eli Lilly quotes Zepbound self-pay at "as low as $299" for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg and above, with that top rate conditional on refilling within 45 days of your last delivery⁴.

There is now also a pill. On 22 December 2025 the FDA approved once-daily oral Wegovy, the first oral GLP-1 for obesity in the US⁵; in the OASIS 4 trial, published in the New England Journal of Medicine, oral semaglutide 25 mg produced a mean body-weight change of −13.6% at week 64 against −2.2% on placebo⁶. Novo lists the pill at "$149 for each month of 1.5 mg and 4 mg", with the 4 mg offer stated as running only until 31 August 2026³. If needles are your barrier, or the budget is, this is the cheapest FDA-approved door currently open.

You still need a prescription for all of it. And every one of these offers carries an expiry date, so confirm the number on the day you buy.

Route 2 — A local prescriber plus a cash pharmacy price

The traditional path still works: see a primary-care doctor or an obesity-medicine clinician, get a prescription, and pay a cash or discount-card price at a pharmacy. It is often more expensive than the manufacturer's own program, but it gives you an in-person relationship and someone local monitoring you — worth a lot if you have other health conditions or are navigating what to tell your OB before starting. It is also the route that catches the things an intake form does not ask about.

Route 3 — Telehealth, with your eyes open

Telehealth is still a legitimate and often convenient way to be evaluated and prescribed, including for the brand drugs above. What has changed is the compounded product many platforms built their pricing on.

The FDA has announced its intent "to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed", naming companies including Hims & Hers, and has warned that violations "may result in legal action without further notice"⁷. Its consumer guidance is blunter still: compounded drugs "do not undergo FDA's review for safety, effectiveness and quality before they are marketed", and "should only be used in patients whose medical needs cannot be met by an FDA-approved drug"⁸.

That same FDA page lists telehealth red flags worth reading before you enter a card number. Among them: a company that "makes claims such as the compounded drug is the same as an FDA-approved drug", that "offers medicine at deep discounts or prices that seem too good to be true", that "does not require a screening and prescription by a licensed doctor before providing medicine", or that "does not have a licensed doctor available to answer questions after you receive your medication"⁸.

A legitimate route always runs through a real prescriber. If a site skips the clinician entirely, that is a red flag, not a shortcut — and the FDA lists it as one.

A related red flag worth adding to that list yourself: collecting payment before you ever speak to a clinician, on terms that call it non-refundable. Liv Body's own Terms of Service state fees are "NOT REFUNDABLE IN WHOLE OR IN PART," and payment is collected before the consult — on top of a funnel whose per-drug pricing cards and its own FAQ quote two different numbers for the same program.

Four worked examples from an August 2026 check show how much reading past the front page still matters even at legitimate-looking telehealth clinics. JustAnswer Weight Loss's public site is a client-rendered app that shows nothing to a plain page load at all — its real catalog and price only surface in the site's own compiled JavaScript, and the number it advertises loudest, $149.97 the first month, becomes $249.97/mo "thereafter." Bioverse is easier to read on price — $129/mo semaglutide, shown consistently — but its own homepage FAQ names two different, non-matching lists of served states in two separate answers, so its own site can't confirm your own coverage even if you ask it directly. Healthicare genuinely holds its price flat across every dose, but its own "44 states" claim and its own 10-state exclusion list don't add up to each other. And Freya Meds headlines "as little as $150/month" on its homepage — the twelve-month prepaid rate — when the plan most new patients actually start on, month to month with no commitment, is $297.

The FDA red flag about a compounded drug being marketed as "the same as an FDA-approved drug" is not hypothetical. Mint Medical Clinic is a real hybrid clinic with two physical Utah locations — genuine in-person accountability — and its own site still calls its compounded medications "FDA-compliant prescription medications," which overstates what's actually true and is exactly the framing the FDA warns readers to watch for. Maves shows the other end of the spectrum: it's LegitScript-certified and states its clinicians are licensed in all 50 states, real trust signals worth checking for on any site you're considering — though even Maves isn't perfectly consistent, since its own homepage banner and its dedicated treatment card quote two different semaglutide prices. On the payment-before-consult red flag specifically: FMmeds is the better model, charging nothing for the initial visit and billing it only once you're approved. Mixx Health & Wellness is the one to read closely — a $125 fee applies if you cancel inside 24 hours, and every payment is stated as final.

What actually stops people, according to the people it stopped

Access is not only about the front door. It is about month seven.

Researchers surveyed 1,659 participants managed for weight loss in a virtual setting — the telehealth route, at scale — and asked what drove them and what stopped them. Discontinuation, they reported, was influenced by treatment costs, unmet weight-loss expectations and side effects, with stigma and affordability described as notable deterrents. The same participants reported that the medication reduced food-related thoughts and improved satiety, and 55% of them had been trying to lose weight for more than ten years before they started⁹.

That last figure is the one to sit with while you compare prices. These are not people looking for a shortcut; most had been at it for a decade. And the thing that most often ended the attempt was not the medicine failing. It was the bill.

How to choose without getting burned

Price the maintenance dose, not the intro dose, because the dose climbs as the drug starts working — and this is a standing cost, not a one-month buy. When semaglutide was stopped in the STEP 4 trial, participants regained much of the weight¹⁰, so plan for a recurring bill rather than a finish line.

Then apply three tests. Is the product FDA-approved, and if not, why not? Is there one flat, all-in monthly price with the clinician included and no step-up as you titrate? And is there a licensed clinician you can actually reach after the box arrives, not just before you pay? Whichever route you pick, take the plan to a clinician who knows your full history before your first dose.